|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
4.49(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
19,582 |
159,721 |
159,721 |
409,721 |
Total Sell Value |
$1,173,232 |
$10,834,513 |
$10,834,513 |
$25,314,056 |
Total People Sold |
1 |
3 |
3 |
3 |
Total Sell Transactions |
1 |
12 |
12 |
22 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kulkarni Samarth |
Chief Executive Officer |
|
2024-01-16 |
4 |
AS |
$62.50 |
$1,250,058 |
D/D |
(20,000) |
187,377 |
|
-13% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2024-01-16 |
4 |
OE |
$19.12 |
$382,400 |
D/D |
20,000 |
207,377 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-05-30 |
4 |
AS |
$63.61 |
$1,621,894 |
D/D |
(25,000) |
387,377 |
|
-33% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-05-30 |
4 |
OE |
$19.12 |
$478,000 |
D/D |
25,000 |
412,377 |
|
- |
|
Morrow Phuong Khanh |
Chief Medical Officer |
|
2023-05-24 |
4 |
D |
$65.91 |
$166,555 |
D/D |
(2,527) |
4,411 |
|
- |
|
Morrow Phuong Khanh |
Chief Medical Officer |
|
2023-05-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,938 |
6,938 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-04-25 |
4 |
AS |
$50.50 |
$1,266,638 |
D/D |
(25,000) |
387,377 |
|
2% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-04-25 |
4 |
OE |
$19.12 |
$478,000 |
D/D |
25,000 |
412,377 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2023-03-13 |
4 |
D |
$43.22 |
$99,622 |
D/D |
(2,305) |
54,844 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-03-13 |
4 |
D |
$43.22 |
$408,170 |
D/D |
(9,444) |
387,377 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2023-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,250 |
55,866 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
391,463 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,833 |
54,899 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,833 |
387,821 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-02-27 |
4 |
AS |
$47.71 |
$1,206,243 |
D/D |
(25,000) |
375,988 |
|
11% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-02-27 |
4 |
OE |
$19.12 |
$478,000 |
D/D |
25,000 |
400,988 |
|
- |
|
Smith Brendan |
Chief Financial Officer |
|
2023-02-21 |
4 |
D |
$48.26 |
$67,178 |
D/D |
(1,392) |
5,072 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2023-02-21 |
4 |
D |
$48.26 |
$94,107 |
D/D |
(1,950) |
52,066 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-02-21 |
4 |
D |
$48.26 |
$307,561 |
D/D |
(6,373) |
375,988 |
|
- |
|
Smith Brendan |
Chief Financial Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,825 |
6,464 |
|
- |
|
Kasinger James R. |
General Counsel and Secretary |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,825 |
54,016 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,250 |
382,361 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-01-27 |
4 |
AS |
$50.60 |
$1,286,798 |
D/D |
(25,000) |
369,111 |
|
19% |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2023-01-27 |
4 |
OE |
$19.12 |
$478,000 |
D/D |
25,000 |
394,111 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2022-12-28 |
4 |
AS |
$40.81 |
$1,023,290 |
D/D |
(25,000) |
369,111 |
|
62% |
|
485 Records found
|
|
Page 2 of 20 |
|
|